This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

SSRIs and delayed orgasm

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • selective serotonin reuptake inhibitors (SSRIs) are a common cause of drug-induced hyperprolactinaemia
    • SSRIs are associated with an approximate eight-fold increased risk of development of galactorrhoea compared with other antidepressants

  • also delayed orgasm or ejaculation is a possible adverse effect in men treated with SSRIs

  • monoamine oxidase inhibitors and tricyclic antidepressants have also been rarely reported to cause galactorrhoea or hyperprolactinaemia

Sexual dysfunction and SSRIs

  • sexual dysfunction occurs through several brain pathways involving increases in serotonin (5-HT), decreases in dopamine (DA) and inhibition of nitric oxide synthase
    • increases in cortico-limbic 5-HT result in decreased sexual desire, ejaculation and orgasm selective serotonin reuptake inhibitor (SSRI)-induced sexual dysfunction occurs in 30%-80% of patients and is a main cause of treatment discontinuation

  • management
    • check PRL - SSRIs can cause drug-induced hyperprolactinaemia

    • seek expert advice

    • pharmacologic methods to reduce sexual dysfunction involve dose reduction, augmentation, or switching medication
      • since dose reduction is the least disruptive strategy it should be considered first, particularly in a responder (1)

      • altering 5-HT receptor antagonism and agonism can have favourable sexual effects, but may cause other adverse event
        • mirtazapine antagonizes 5-HT2 and 5-HT3 receptors and it has been successfully used as an add-on therapy for antidepressant-induced sexual dysfunction
          • however associated with a relatively high rate of weight gain
        • other possible augmentation therapies that have been used include cyproheptidine and buspirone

      • phospho-diesterase inhibitors e.g. sildenafil have demonstrated evidence for the reversal of SSRI-induced sexual side effects in men

      • DA release enhances sexual function
        • evidence supports adjunctive bupropion XL for reversing SSRI-induced sexual dysfunction in men and women across the domains of desire, arousal and orgasm

      • several antidepressants, including bupropion, moclobemide, and mirtazapine have little to no effect on sexual function compared with placebo when used as a monotherapy

      • evidence suggests exercise can improve sexual function in SSRI-induced sexual dysfunction

Reference:

  • Rizvi SJ1, Kennedy SH.Management strategies for SSRI-induced sexual dysfunction. J Psychiatry Neurosci. 2013 Sep;38(5):E27-8.

 


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.